Parkinson’s is a debilitating neurodegenerative disease affecting more than 1 million Americans with the addition of 60,000 new cases annually.
- Parkinson’s disease is a chronic and progressive disease. There is no cure.
- Present clinical therapies for Parkinson’s disease that are on the market today are focused on treating the symptoms and fall short of addressing the on-going destruction of dopamine neurons.
- The ability of symptom treating medications designed to replenish dopamine levels become overwhelmed by further loss of dopaminergic neuronal cells and the patient’s condition continues to worsen over the long term.
- The prognosis of patients being treated conventionally is very limited while disease progression continues unabated.
The New Therapy Toward the Cure for Parkinson's Disease
SynapCyte has been awarded exclusive licensing rights to a small molecular compound that can stimulate the proliferation of neural stem cells to regenerate dopamine producing neurons.
- SynapCyte could revolutionize the way in which Parkinson’s disease patients are treated. Instead of symptomatic treatment with debilitating dopamine replenishing drugs, KS-217 would actually trigger production of new neurons capable of naturally producing the critical dopamine.
- KS-217 could produce new neurons with no ill side effects.
SynapCyte's KS-217 therapy for the treatment of Parkinson's Disease
SynapCyte’s KS-217 is a small molecular compound that can stimulate the proliferation of neural stem cells, which generate dopamine producing neurons.
SynapCyte has made great gains in testing its Parkinson’s treatment formulation (KS-217). Laboratory studies employing model rats have demonstrated an amazing proliferation of cells in the brain after treated with only 3mg/kg of KS-217 (F,G,H). Slides A, B, C, and D show the home of neural stem cells, called sub ventricular zone, treated with SynapCyte’s KS-217 in age impaired (B) and age un-impaired (D) rodents as well as those treated with vehicle controls (A,C). Brown dots are the cells newly proliferated. It is clear that KS-217 promoted the proliferation of neural stem cells in the brain and also increased a migration of newly formed stem cells towards the cortex (arrows in B and D). These remarkable migrations were observed in age impaired more than unimpaired animals, indicating the need of the neuronal regeneration these animals motor cortex region of the brain responsible for the control and execution of voluntary muscle movement. Resulting that significant (500%) increase in stem cell derived cells in the motor cortex where the most important part of the brain to controls voluntary movements (E).
This figure demonstrates the increased proliferation of stem cells in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mice after KS-217 treatment. MPTP is known to kill dopaminergic neurons mimicking Parkinson’s disease effects of experimental treatments. The color slides on the left reflect stem cell levels in the sub-ventricular zone (SVZ) and dentate gyrus (DG) of hippocampus of untreated MPTP mouse brains, and the slides on the right capture the same area of the brain following treatment with SynapCyte’s KS-217. The red signals on the KS-217 slides on the right panels after treated with KS-217 clearly demonstrate increased stem cell proliferation in treated animals. In addition, increased staining with DCX (green) indicates increased generation of young neuron cells. The bar chart depicts the significant quantitative increase in the neural stem cell number within the SVZ and DG of KS-217 treated animals versus untreated controls at a 95% confidence level for the DG and a 99% confidence level for the SVZ.